Dejerine-Sottas disease (DSD), also called hereditary motor and sensory neuropathy type III (HMSNIII), is a severe, infantile-onset demyelinating polyneuropathy syndrome that may be associated with point mutations in either the PMP22 gene, PO gene, EGR2 gene or the PRX gene (for the recessive form). It shares considerable clinical and pathologic features with CMT1. Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal dominant disorder that results in a recurrent, episodic demyelinating neuropathy. HNPP is associated with a 1.5-Mb deletion in chromosome 17p11.2-p12 that results in reduced expression of the PMP22 gene. CMT1A and HNPP are reciprocal duplication/deletion syndromes that originate from unequal crossover during germ cell meiosis. 2 Southern blots, pulsed-field gel electrophoresis (PFGE), fluorescence in situ hybridization (FISH), rapid real-time PCR gene dosage, and polymorphic marker analysis are the currently used diagnostic methods for CMT1A and HNPP detection. 3 In a recent study comparing real-time PCR with the other methods currently used for the diagnosis of CMT, by using a combination of junction fragment PCR, analysis of microsatellite markers, and PFGE, 76 unrelated patients with 17p12 duplication were identified. In these patients, junction fragment PCR detected 63% of cases of duplication, the microsatellite markers method revealed 74%, while the combined use of microsatellite markers and junction fragment PCR revealed 91% of cases of CMT1A. PFGE detected 100% of the cases with duplication, even in the presence of atypical 17p12 duplication. Real-time PCR detected 100% of the cases with CMT1A and was comparable to PFGE. However, in contrast to PFGE, real-time PCR does not need fresh blood, and minimizes diagnosis time and cost. 4 A conclusion might be made that the previous methods are time-consuming, laborintensive, and have some significant limitations, especially difficulties in interpretation of dosage for different alleles. 5 As reported in this issue of the Journal of the Chinese Medical Association, Lin et al 6 developed allele-specific primers to amplify genomic DNA of patients with CMT1A and HNPP, which provides a rapid quantitative PCR method for determining gene copy number for the identification of DNA duplication or deletion occurring in CMT1A or HNPP. They could identify the mutations by means of agarose gel electrophoresis after PCR amplification without restriction enzyme digestion from 33 (82.5%) of the 40 CMT1A and 19 (76.0%) of the 25 HNPP samples. All CMT1A and HNPP patients had previously been identified with microsatellite mapping. Stringently specific primers were used to overcome the problem of nonspecific amplification and provide a rapid, all-or-none PCR product and efficient screening test for CMT1A and HNPP. This new method is also faster and easier than currently available methods. The question has been raised whether the absence of PCR products in some patients was related to technical reasons in the CMT1 or HNPP assays or not, and the design of primers for multiplex PCR has been suggested for improving the detection rate.
Currently, mutations in multiple different genes expressed in Schwann cells and neurons cause a variety of overlapping clinical phenotypes of CMT and HNPP.
Recent studies have clarified the molecular pathways involved in the pathogenesis of these disorders, and for the first time provide rational treatment strategies for the most common forms of CMT, especially CMT1 and HNPP. 7 Taken together, results from these studies support the concept that genetic causes of CMT serve as a living microarray system to identify molecules necessary for normal peripheral nervous system function. When we can make sense of these microarrays, we are likely to understand the pathogenesis and develop rational therapies for CMT1A and HNPP. 7 
